Clinical trials: Oxaliplatin
Neuroendocrine Tumors, Neoplasm Metastasis
DEBOXA for Inoperable NET Liver Metastases
A prospective clinical trial to study the safety and effectiveness of Transcatheter Artery Chemotherapy and Embolization (TACE) using CalliSpheres Drug-Eluting Beads with oxaliplatin (DEBOXA) in treating patients who have…
- Conditions
- Neuroendocrine Tumors, Neoplasm Metastasis, Liver
- Trial name
- NCT03881306
- Testing
- D-TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiangya Hospital of Central South University
Quality of Life, Chemotherapy-induced Peripheral Neuropathy
Hilotherapy-study on Prevention of Oxaliplatin-induced Peripheral Neuropathy
Effectiveness of hilotherapy for the prevention of oxaliplatin-induced peripheral neuropathy and pain in the treatment of gastrointestinal tumors: A randomized controlled trial.
- Trial name
- HILO-OXALI (NCT04913376)
- Testing
- Hilotherapy
- Where
- Belgium
- Volunteers
- 66 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Colonic Neoplasms
MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
To evaluate the FOLFOX regimen versus LV5FU2 in the adjuvant treatment of stage II and III colon cancer. Primary objective: Disease Free Survival (DFS) Secondary objective: Overall Survival (OS), safety (including long term…
- Trial name
- NCT00275210
- Testing
- Oxaliplatin (SR96669)
- Where
- 19 sites in Australia, Austria and 17 more
- Volunteers
- 2,246 people
- Sponsor
- Sanofi
Advanced Colorectal Cancer, Adenocarcinoma of the Colon
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
To determine the effect of ABT-869 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 on disease progression in advanced colorectal cancer.
- Conditions
- Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT00707889
- Testing
- ABT-869, bevacizumab, oxaliplatin
- Where
- 46 sites in United States, Australia and 12 more
- Volunteers
- 159 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma
In patients with relapsed or refractory diffuse DLBCL who have not achieved complete remission in the mid-term, the treatment with Glofit+GemOx regimen is used.
- Trial name
- NCT07480850
- Testing
- Glofitamab, Gemcitabin, Oxaliplatin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer, RCT
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative ivonescimab in combination with S-1 and oxaliplatin (SOX) is effective in treating locally advanced gastric or gastroesophageal junction (GEJ)…
- Trial name
- Huaxi (NCT07374250)
- Testing
- Ivonescimab (20mg/kg Q3W), Oxaliplatin, S-1
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sichuan University
Stomach Neoplasms
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer
The purpose of this study is to determine the efficacy and safety of oxaliplatin and s1 as first-line treatment of advanced gastric cancer.
- Trial name
- NCT01531452
- Testing
- Oxaliplatin, s1
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Chinese Academy of Medical Sciences
Colorectal Cancer
Azacitidine and CAPOX in Metastatic Colorectal Cancer
The goal of the Phase I portion of this study is to find the highest tolerable dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can be given to patients with metastatic colorectal cancer.
- Trial name
- NCT01193517
- Testing
- Azacitidine, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006050
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- 3 sites in France
- Sponsor
- UNICANCER
Metastatic Pancreatic Cancer
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.
- Trial name
- NCT05929885
- Testing
- Low Dose OXIRI (LD-OXIRI)
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- National Cancer Centre, Singapore
Peritoneal Neoplasms
A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis
This study prospectively evaluates a multidisciplinary approach to patients with intraperitoneal carcinomatosis at Washington University.
- Trial name
- NCT00352755
- Testing
- Surgical debulking with peritonectomy, Intraperitoneal 5FU, FOLFOX
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach
Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach
The purpose of this study is to determine the rate of complete pathological responses (percentage of patients with pCR referring to the total number of enrolled and eligible patients), as evaluated centrally by a reference…
- Trial name
- HerFLOT (NCT01472029)
- Testing
- 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab, Post-operative treatment trastuzumab mono therapy
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Gastric Cancer
Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, S-1, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00985556
- Testing
- capecitabine, oxaliplatin, tegafur-gimeracil-oteracil potassium
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Yonsei University
First-line Treatment of Metastatic Pancreatic Cancer
Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
This study is a randomized, open-label, multicenter Phase III clinical trial designed to evaluate the efficacy and safety of Irinotecan Hydrochloride Liposome Injection (II) combined with oxaliplatin and 5-FU/LV versus…
- Trial name
- NCT07238283
- Testing
- Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
- Where
- China
- Volunteers
- 662 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastro Esophageal Junction Cancer, Stomach Cancer
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Trial name
- NCT03488667
- Testing
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Paclitaxel in Treating Patients With Metastatic or Unresectable Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004173
- Testing
- oxaliplatin, paclitaxel
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Hepatocellular Carcinoma
the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma
evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.
- Trial name
- NCT03777475
- Testing
- transarterial infusion
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Sun Yat-sen University
Advanced Primary Liver Cancer
Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer
Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin in the First -line treatment of advanced primary liver cancer
- Trial name
- NCT03166553
- Testing
- Elemene
- Where
- 10 sites in China
- Volunteers
- 150 people
- Sponsor
- BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Colorectal Cancer
Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer
RATIONALE: 5FU based neoadjuvant chemoradiation (nCRT) is the standard of care for Stage II/III rectal cancer. Pathologic complete response (pCR) and downstaging have been associated with improved outcomes.
- Trial name
- NCT00831181
- Testing
- 5-FU, Oxaliplatin, leucovorin
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Beth Israel Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.